Vanesa Bernal

Dr. Vanesa Bernal

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in Cells
Verified
Journal Article
Open access
PDF file
MLMarta López-Yus
Marta López-Yus
CHCarlos Hörndler
Carlos Hörndler
SBSOFIA sofia BORLAN
SOFIA sofia BORLAN
VBVanesa Bernal
Vanesa Bernal
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
Adipose tissue (AT), once considered a mere fat storage organ, is now recognized as a dynamic and complex entity crucial for regulating human physiology, including metabolic processes, energy balance, and immune responses. It comprises mainly two types: white adipose tissue (WAT) for energy storage and brown adipose tissue (BAT) for thermogenesis, with beige adipocytes demonstrating the plasticity of these cells. WAT, beyond lipid storage, is involved in various metabolic activities, notably lipogenesis and lipolysis, critical for maintaining energy homeostasis. It also functions as an endocrine organ, secreting adipokines that influence metabolic, inflammatory, and immune processes. However, dysfunction in WAT, especially related to obesity, leads to metabolic disturbances, including the inability to properly store excess lipids, resulting in ectopic fat deposition in organs like the liver, contributing to non-alcoholic fatty liver disease (NAFLD). This narrative review delves into the multifaceted roles of WAT, its composition, metabolic functions, and the pathophysiology of WAT dysfunction. It also explores diagnostic approaches for adipose-related disorders, emphasizing the importance of accurately assessing AT distribution and understanding the complex relationships between fat compartments and metabolic health. Furthermore, it discusses various therapeutic strategies, including innovative therapeutics like adipose-derived mesenchymal stem cells (ADMSCs)-based treatments and gene therapy, highlighting the potential of precision medicine in targeting obesity and its associated complications.

4 September 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
VBVanesa Bernal
Vanesa Bernal
DDDiego Casas Deza
Diego Casas Deza
LLLaura Letona-Giménez
Laura Letona-Giménez
NLNatalia de la Llama-Celis
Natalia de la Llama-Celis
PCPilar Calmarza
Pilar Calmarza
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with abnormal liver function tests. We hypothesized that early altered liver biochemistries at admission might have different clinical relevance than subsequent changes during hospitalization. A single-center retrospective study was conducted on 540 consecutive hospitalized patients, PCR-diagnosed with SARS-CoV-2. Liver test abnormalities were defined as the elevation of either gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST), above the upper limit of normality set by our laboratory. Linear mixed models (LMM) evaluated longitudinal associations, incorporating all available follow-up laboratory chemistries. By the end of the follow-up period, 502 patients (94.5%) were discharged (109 (20.5%) died). A total of 319 (64.3%) had at least one abnormal liver test result at admission. More prevalent were elevated AST (40.9%) and GGT (47.3%). Abnormalities were not associated with survival but with respiratory complications at admission. Conversely, LMM models adjusted for age and sex showed that longitudinal increases during hospitalization in ferritin, GGT, and alkaline phosphatase (ALP), as well as a decreased albumin levels, were associated with reduced survival. This dual pattern of liver damage might reconcile previous conflicting reports. GGT and ALP trajectories could be useful to determine who might need more surveillance and intensive care.

3 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
SESilvia Espina
Silvia Espina
ASAlejandro Sanz-Paris
Alejandro Sanz-Paris
YGYolanda Gonzalez-Irazabal
Yolanda Gonzalez-Irazabal
PPPatricia Pérez-Matute
Patricia Pérez-Matute
FAFernando Andrade
Fernando Andrade
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
β-Hydroxy-β-methylbutyrate (HMB) supplementation increases muscle and strength mass in some muscle-wasting disorders. Malnutrition and sarcopenia are often present in liver cirrhosis. We aimed to investigate the effects of oral HMB supplementation on changes in body composition and liver status in patients with cirrhosis and malnutrition. In a randomized, controlled, double-blind trial, 43 individuals were randomized to receive twice a day and for 12 weeks an oral nutritional supplement (ONS) enriched with 1.5 g of calcium HMB per bottle or another supplement with similar composition devoid of HMB. Inclusion criteria were liver cirrhosis with at least one previous decompensation and clinical malnutrition. Liver function, plasma biochemistry analyses, and physical condition assessment were carried out at baseline, then after six and 12 weeks of supplementation. A total of 34 patients completed the clinical trial. An improvement in liver function and an increase in fat mass index were observed in both groups. None of the two ONS changed the fat-free mass. However, we observed an upward trend in handgrip strength and a downward trend in minimal hepatic encephalopathy in the HMB group. At the end of the trial and regardless of the supplement administered, fat mass content increased with no change in fat-free mass, while liver function scores and nutritional analytic markers also improved.

25 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
SESilvia Espina
Silvia Espina
YGYolanda Gonzalez-Irazabal
Yolanda Gonzalez-Irazabal
ASAlejandro Sanz-Paris
Alejandro Sanz-Paris
MLMarta López-Yus
Marta López-Yus
MSMARIA PILAR GARCIA SOBREVIELA
MARIA PILAR GARCIA SOBREVIELA
José Miguel Arbones-MainarJosé Miguel Arbones-Mainar
José Miguel Arbones-Mainar
Low plasma levels of branched chain amino acids (BCAA) in liver cirrhosis are associated with hepatic encephalopathy (HE). We aimed to identify a metabolic signature of minimal hepatic encephalopathy (MHE) in malnourished cirrhotic patients and evaluate its modification with oral nutritional supplements (ONS) enriched with ß-Hydroxy-ß-methylbutyrate (HMB), a derivative of the BCAA leucine. Post hoc analysis was conducted on a double-blind placebo-controlled trial of 43 individuals with cirrhosis and malnutrition, who were randomized to receive, for 12 weeks, oral supplementation twice a day with either 220 mL of Ensure® Plus Advance (HMB group, n = 22) or with 220 mL of Ensure® Plus High Protein (HP group, n = 21). MHE evaluation was by psychometric hepatic encephalopathy score (PHES). Compared to the HP group, an HMB-specific treatment effect led to a larger increase in Val, Leu, Phe, Trp and BCAA fasting plasma levels. Both treatments increased Fischer’s ratio and urea without an increase in Gln or ammonia fasting plasma levels. MHE was associated with a reduced total plasma amino acid concentration, a reduced BCAA and Fischer´s ratio, and an increased Gln/Glu ratio. HMB-enriched ONS increased Fischer´s ratio without varying Gln or ammonia plasma levels in liver cirrhosis and malnutrition, a protective amino acid profile that can help prevent MHE.

13 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
POPablo Cañamares Orbís
Pablo Cañamares Orbís
VBVanesa Bernal
Vanesa Bernal
OSOlivia Sierra-Gabarda
Olivia Sierra-Gabarda
DDDiego Casas Deza
Diego Casas Deza
GGGuillermo García-Rayado
Guillermo García-Rayado
Alberto LuéAlberto Lué
Alberto Lué
Liver and pancreatic diseases have significant consequences on nutritional status, with direct effects on clinical outcomes, survival, and quality of life. Maintaining and preserving an adequate nutritional status is crucial and should be one of the goals of patients with liver or pancreatic disease. Thus, the nutritional status of such patients should be systematically assessed at follow-up. Recently, great progress has been made in this direction, and the relevant pathophysiological mechanisms have been better established. While the spectrum of these diseases is wide, and the mechanisms of the onset of malnutrition are numerous and interrelated, clinical and nutritional manifestations are common. The main consequences include an impaired dietary intake, altered macro and micronutrient metabolism, energy metabolism disturbances, an increase in energy expenditure, nutrient malabsorption, sarcopenia, and osteopathy. In this review, we summarize the factors contributing to malnutrition, and the effects on nutritional status and clinical outcomes of liver and pancreatic diseases. We explain the current knowledge on how to assess malnutrition and the efficacy of nutritional interventions in these settings.

1 April 2009 in Transplantation Proceedings
Verified
Journal Article
Closed access
VBVanesa Bernal
Vanesa Bernal
IPI. Pascual
I. Pascual
PEP. Esquivias
P. Esquivias
AGA. García-Gil
A. García-Gil
JMJ.M. Mateo
J.M. Mateo
MSM.A. Simón
M.A. Simón